Multiple Sclerosis Clinical Research Trials

Active

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with Glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis

  • Status:Enrolling
  • Sponsor: Novartis Pharmaceuticals
  • Click here for more information

Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy (PASSAGE)

  • Status:Enrolling
  • Sponsor: Novartis Pharmaceuticals
  • Click here for more information